The overall goal of this imaging trial is to evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.~To characterize [18F]MNI-952, a PET radioligand for imaging tau.~To visually and quantitatively assess brain uptake and pharmacokinetics of [18F]MNI-952, a PET imaging marker for tau pathology in individuals with Progressive Supranuclear Palsy (PSP) or Alzheimer's disease (AD) and compare with healthy volunteers (HV).~To evaluate the safety of a single injection of [18F]MNI-952.~To compare the distribution of tau (using [18F]MNI-952) and Aâ (using florbetapir) in AD subjects.
The overall goal of this imaging trial is to evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.